Background
The LEAD (Liraglutide Effect and Action in Diabetes) program comprised six Phase 3 trials evaluating liraglutide across the spectrum of type 2 diabetes treatment. LEAD-6 was a direct head-to-head comparison between liraglutide and exenatide — the first approved GLP-1 receptor agonist — representing the pivotal trial establishing liraglutide’s clinical differentiation within the GLP-1 class.
Both agents share the GLP-1 receptor agonist mechanism (glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, CNS satiety signaling) but differ in structure, half-life, and dosing frequency. Liraglutide’s human GLP-1 homology (97%) and albumin-binding fatty acid chain confer a 13-hour half-life enabling once-daily dosing, versus exenatide’s twice-daily requirement and higher immunogenicity.
Methods
Design: Open-label, active-comparator controlled, parallel-group Phase 3 trial (26 weeks)
Population: 464 adults with T2D inadequately controlled on maximally tolerated metformin ± sulfonylurea (HbA1c 7–11%); mean HbA1c 8.2%
Interventions:
- Liraglutide 1.8 mg subcutaneous once daily (morning)
- Exenatide 10 µg subcutaneous twice daily (pre-meals)
Primary endpoint: Change from baseline in HbA1c at 26 weeks
Key Findings
Primary Efficacy:
| Endpoint | Liraglutide 1.8 mg | Exenatide 10 µg BID | p-value |
|---|---|---|---|
| HbA1c change | −1.12% | −0.79% | < 0.0001 |
| HbA1c < 7.0% achieved | 54% | 43% | < 0.01 |
| HbA1c < 6.5% achieved | 35% | 20% | < 0.001 |
Liraglutide achieved 0.33% greater HbA1c reduction — a clinically and statistically significant difference.
Secondary Efficacy:
| Parameter | Liraglutide | Exenatide |
|---|---|---|
| Weight loss (kg) | −3.24 | −2.87 |
| Fasting plasma glucose change | −29.0 mg/dL | −11.0 mg/dL |
| Systolic BP change (mmHg) | −2.6 | −1.0 |
| Postprandial glucose | Similar | Similar |
- Fasting glucose reduction was substantially greater with liraglutide, consistent with its 24-hour GLP-1 receptor coverage vs. exenatide’s twice-daily profile
- Weight loss similar between groups despite liraglutide’s superior glycemic control
Tolerability Differentiation:
| AE | Liraglutide | Exenatide |
|---|---|---|
| Minor hypoglycemia | 1.93 events/patient-year | 2.60 events/patient-year |
| Nausea (any) | 25.5% | 28.0% |
| Nausea (persistent at end) | 8.6% | 18.1% |
| Anti-drug antibodies | 9.0% | 54.8% |
- Persistent nausea markedly lower with liraglutide (8.6% vs. 18.1%) — important real-world tolerability advantage
- Immunogenicity substantially lower (9% vs. 55% antibody formation) — with exenatide antibodies correlating with reduced glycemic control
Clinical Significance
- Head-to-head GLP-1 superiority: LEAD-6 established liraglutide as the superior GLP-1 agent for HbA1c reduction, weight loss, and tolerability at the time of approval
- Once-daily convenience: The equivalent or superior efficacy with simpler once-daily dosing versus twice-daily exenatide has significant real-world adherence implications
- Fasting glucose advantage: Liraglutide’s full 24-hour GLP-1 receptor coverage produces superior fasting glucose lowering — the dominant driver of HbA1c reduction for most T2D patients
- Immunogenicity: The nearly 6-fold lower antibody formation rate with liraglutide addresses a real-world concern with exenatide’s secondary efficacy loss over time
Limitations
- Open-label design (could not blind due to different devices and dosing frequencies); potential for assessment bias
- 26-week duration may not capture long-term differences in durability or cardiovascular outcomes
- Head-to-head against exenatide (twice-daily formulation); comparison to weekly exenatide or semaglutide not addressed
- Mean baseline HbA1c of 8.2% may not represent patients with more advanced T2D
- No cardiovascular outcomes data (subsequently addressed by the LEADER trial)